Drugs / AdMA3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02285816 | Jan 2015 → Sep 2019 overdue | — | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdMA3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02285816 ↗ |
| Action | Deplete | “selectively killing cancer cells” NCT02285816 ↗ |
| Modality | Vaccine | “Priming component of Oncolytic Vaccine” NCT02285816 ↗ |
| Route | Intramuscular | “administered IM on day (-14)” NCT02285816 ↗ |